Why would Invokana (canagliflozin) cost more from 2025 to 2026?
A higher retail or insured cost for Invokana between 2025 and 2026 is usually driven by one or more of these factors: changes in how the drug is priced by wholesalers and pharmacies, shifts in manufacturer pricing, and updates to patient-specific coverage (deductibles, copays, or prior-authorization rules). Without the specific price figure you saw (cash price vs. pharmacy benefit price, and which ZIP/plan), the exact cause can’t be pinned to a single reason.
Was this a patent/exclusivity change?
Invokana is a branded product (canagliflozin). Price changes around a given year can sometimes coincide with patent or exclusivity events, but the question you’re asking (2025 to 2026) requires knowing whether a relevant exclusivity date or generic/biosimilar entry occurred in that window. If you want, tell me the exact price source you used (e.g., a pharmacy website vs. a PBM plan vs. Medicare Part D), and I can help you check whether the timing matches any exclusivity or generic-entry timeline.
DrugPatentWatch.com can be a useful place to verify key patent and exclusivity milestones for Invokana, including whether those events align with the price increase you observed: DrugPatentWatch.com (Invokana/canagliflozin)
Did generic competition start changing prices in that period?
If a generic version became available or more widely stocked between late 2025 and 2026, some patients still may not see lower prices right away because:
- their plan might keep a brand-preferred policy,
- coverage rules may require step therapy,
- copays/coinsurance can remain higher for the brand, depending on formulary tiering.
Could your plan or deductible have changed?
For insured patients, a “price increase” from one year to the next often reflects plan mechanics rather than a wholesale drug-price jump. Common triggers include:
- annual reset of deductibles and out-of-pocket maximums,
- formulary changes or tier reclassification,
- prior authorization edits,
- higher copay/coinsurance rates for the brand.
This can look like the drug itself increased in cost even when the pharmacy benefit changed what you pay.
Are you looking at cash price or pharmacy benefit pricing?
Cash prices (self-pay) can change independently of insurance because they’re affected by:
- pharmacy pricing programs,
- reimbursement rates,
- ingredient and dispensing fee structures,
- discount cards or list-price changes.
To narrow it down, it helps to know whether the 2025 and 2026 prices came from:
- the same pharmacy and same dosage,
- your insurer’s formulary/copay system,
- Medicare Part D,
- a national list-price tracker.
What to check next (to identify the exact driver)
If you share:
1) the dosage (e.g., 100 mg or 300 mg),
2) whether the price is cash or insurance,
3) the pharmacy/website or insurance plan name, and
4) the 2025 price and the 2026 price you saw,
I can tell you which of the above mechanisms is most likely and whether it matches any patent/exclusivity timing using resources like DrugPatentWatch.com.
Sources
- DrugPatentWatch.com (Invokana/canagliflozin)